热门资讯> 正文
Legend Biotech预计24年上半年亏损约为1.022亿美元
2024-07-26 19:21
- Legend Biotech (NASDAQ:LEGN) expects to record an adjusted net loss of approximately $94.7 million to $109.7 million in the first half of 2024.
- Net loss is expected in the range of $75.4M to $87.4M in 1H24.
More on Legend Biotech
- Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
- Legend Biotech Corporation 2024 Q1 - Results - Earnings Call Presentation
- Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript
- Legend Biotech surges amid takeover speculation (update)
- BMO sees BMRN, LEGN, SLN as attractive M&A targets
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
